- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 89 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- May 2024
- 135 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- December 2024
- 200 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- May 2024
- 133 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Drug Pipelines
- July 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 278 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- December 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2025
- 278 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- August 2022
- 70 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2022
- 166 Pages
Global
From €7130EUR$7,500USD£5,990GBP

Amyloidosis is a rare endocrine and metabolic disorder caused by the accumulation of abnormal proteins in the body's organs and tissues. Treatment for amyloidosis typically involves a combination of drugs, including chemotherapy, corticosteroids, and immunosuppressants. The amyloidosis drug market is expected to grow in the coming years due to the increasing prevalence of the disease and the development of new drugs.
The amyloidosis drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of the disease. Some of the major players in the market include Pfizer, Novartis, Sanofi, Merck, and Johnson & Johnson. These companies are focusing on developing new drugs and expanding their product portfolios to meet the growing demand for amyloidosis treatments. Show Less Read more